Table 3.
Overall, N=73 | Early stage NSCLC, n=48 | Late stage NSCLC, n=25 | ||||
---|---|---|---|---|---|---|
VDR expression | Unadjusted HR (95% CI) |
Adjusted HR (95% CI) a |
Unadjusted HR (95% CI) |
Adjusted HR (95% CI)b |
Unadjusted HR (95% CI) |
Adjusted HR (95% CI) b |
Nuclear VDR | ||||||
Low | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
High | 0.52 (0.25-1.09) |
0.36 (0.17-0.79) |
0.59 (0.22-1.57) |
0.34 (0.11-1.09) |
0.39 (0.13-1.19) |
0.39 (0.11-1.34) |
P | 0.085 | 0.011 | 0.29 | 0.069 | 0.098 | 0.135 |
Cytoplasmic VDR | ||||||
Low | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
High | 0.99 (0.54-1.81) |
1.28 (0.65-2.49) |
1.23 (0.55-2.76) |
1.45 (0.58-3.62) |
0.93 (0.35-2.49) |
1.64 (0.49-5.47) |
P | 0.963 | 0.478 | 0.621 | 0.433 | 0.885 | 0.418 |
VDR: Vitamin D receptor; OS: Overall survival; NSCLC: Non-small cell carcinoma
Adjusted for stage, age, histology, sex, smoking status
Adjusted for age, histology, sex, smoking status